Here are the DEF 14A proxy statements from Vera Therapeutics, Inc. (VERA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow VERA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VERA filings page.
Vera Therapeutics, Inc. has called its 2026 Annual Meeting of Stockholders for May 21, 2026, to be held exclusively online via webcast. Holders of Class A common stock at the March 24, 2026 record date, when 71,713,905 shares were outstanding, may vote.
Stockholders will vote on electing three Class II directors to terms ending at the 2029 meeting, ratifying KPMG LLP as independent auditor for 2026, and approving an advisory "say‑on‑pay" resolution on executive compensation. The board recommends voting for all three proposals.
The proxy describes Vera’s classified 11‑member board, committee structure, and independence determinations, and details executive pay practices emphasizing performance‑based annual bonuses and multi‑year equity awards. It also outlines stock ownership of significant investors and insiders, governance policies (including a clawback and insider trading policy), and procedures for submitting future stockholder proposals and director nominations.